Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

作者
Antje Wick,Oliver Bähr,Martin Schüler,Kristoffer Staal Rohrberg,Sant P. Chawla,Filip Jankú,David Schiff,Volker Heinemann,Yoshitaka Narita,Heinz‐Josef Lenz,Masafumi Ikeda,Yuichi Ando,Wolfgang Wick,Joachim Peter Steinbach,Michael C. Burger,Katharina Johanna Wenger,Ulrik Lassen,Kamalesh Kumar Sankhala,Cristiana Roggia,Isabelle Genvresse
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:27 (10): 2723-2733 被引量:73
标识
DOI:10.1158/1078-0432.ccr-20-4256
摘要

Abstract Purpose: BAY1436032, an inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), was active against multiple IDH1-R132X solid tumors in preclinical models. This first-in-human study was designed to determine the safety and pharmacokinetics of BAY1436032, and to evaluate its potential pharmacodynamics and antitumor effects. Patients and Methods: The study comprised of dose escalation and dose expansion cohorts. BAY1436032 tablets were orally administered twice daily on a continuous basis in subjects with mIDH1 solid tumors. Results: In dose escalation, 29 subjects with various tumor types were administered BAY1436032 across five doses (150–1,500 mg twice daily). BAY1432032 exhibited a relatively short half-life. Most evaluable subjects experienced target inhibition as indicated by a median maximal reduction of plasma R-2-hydroxyglutarate levels of 76%. BAY1436032 was well tolerated and an MTD was not identified. A dose of 1,500 mg twice daily was selected for dose expansion, where 52 subjects were treated in cohorts representing four different tumor types [lower grade glioma (LGG), glioblastoma, intrahepatic cholangiocarcinoma, and a basket cohort of other tumor types]. The best clinical outcomes were in subjects with LGG (n = 35), with an objective response rate of 11% (one complete response and three partial responses) and stable disease in 43%. As of August 2020, four of these subjects were in treatment for >2 years and still ongoing. Objective responses were observed only in LGG. Conclusions: BAY1436032 was well tolerated and showed evidence of target inhibition and durable objective responses in a small subset of subjects with LGG.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
洁净山柏发布了新的文献求助10
1秒前
充电宝的应助被QLK采纳,获得10
1秒前
3秒前
万能图书馆的应助被顺利采纳,获得10
5秒前
6秒前
哈哈哈完成签到,获得积分10
6秒前
6秒前
钟美蒂的阴灵完成签到,获得积分10
6秒前
jiyi完成签到,获得积分10
7秒前
我爱吃菜完成签到 ,获得积分10
7秒前
8秒前
嘿嘿发布了新的文献求助10
10秒前
11秒前
PPP发布了新的文献求助10
11秒前
瞿霞完成签到 ,获得积分10
12秒前
12秒前
ffffabab完成签到,获得积分10
13秒前
16秒前
xixi发布了新的文献求助10
17秒前
ffffabab发布了新的文献求助10
19秒前
我是老大的应助被舒适沛蓝采纳,获得10
19秒前
19秒前
科目三的应助被THM666采纳,获得10
19秒前
kathtsao完成签到 ,获得积分10
21秒前
wg发布了新的文献求助10
21秒前
大气十三发布了新的文献求助10
21秒前
充电宝的应助被dit采纳,获得10
24秒前
BBF3完成签到 ,获得积分10
24秒前
25秒前
25秒前
应樱完成签到 ,获得积分0
25秒前
25秒前
共享精神的应助被有趣的桃采纳,获得10
26秒前
Nole的应助被samantha采纳,获得10
28秒前
jiyi关注了科研通微信公众号
29秒前
29秒前
酷波er的应助被曹丹采纳,获得10
29秒前
fantasy的应助被ww采纳,获得10
30秒前
俊逸梦蕊完成签到,获得积分10
30秒前
跳跃芷蕊完成签到,获得积分10
31秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188563
求助须知:如何正确求助?哪些是违规求助? 9576328
关于积分的说明 21846521
捐赠科研通 7786563
什么是DOI,文献DOI怎么找? 3435354
关于科研通互助平台的介绍 2559627
邀请新用户注册赠送积分活动 2482336